The Spectrum of Atherosclerotic Coronary Artery Disease in HIV Patients

Grinspoon SK, Grunfeld C, Kotler DP, et al.: State of the science conference: initiative to decrease cardiovascular risk and increase quality of care for patients living with HIV/AIDS: executive summary. Circulation 2008, 118:198–210.

Grinspoon S, Carr A: Cardiovascular risk and body fat abnormalities in HIV-infected adults. N Engl J Med 2005, 352:48–62.

Ho JE, Hsue PY: Cardiovascular manifestations of HIV infection. Heart 2009, 95:1193–1202.

Palella FJ Jr, Delaney KM, Moorman AC, et al., for HIV Outpatient Study Investigators: Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med 1998, 338:853–860.

Currier JS, Lundgren JD, Carr A, et al.: Epidemiological evidence for cardiovascular disease in HIV-infected patients and relationship to highly active antiretroviral therapy. Circulation 2008, 118:e29–35.

Hsue PY, Squires K, Bolger AF, et al.: Screening and assessment of coronary heart disease in HIV-infected patients. Circulation 2008, 118:e41–47.

Currier JS, Taylor A, Boyd F, et al.: Coronary heart disease in HIV-infected individuals. J Acquir Immune Defic Syndr 2004, 33:506–512.

Triant VA, Lee H, Hadigan C, Grinspoon SK: Increased acute myocardial infarction rates and cardiovascular risk factors among patients with human immunodeficiency virus disease. J Clin Endocrinol Metab 2007, 92:2506–2512.

Klein D, Hurley L, Quesenberry CB, et al.: Do protease inhibitors increase the risk for coronary heart disease in patients with HIV-1 infection? JAIDS 2002, 30:471–477.

Tabib A, Leroux C, Mornex JF, et al.: Accelerated coronary atherosclerosis and arteriosclerosis in young human-immunodeficiency-virus-positive patients. Coron Artery Dis 2000, 11:41–46.

Micheletti RG, Fishbein GA, Fishbein MC, et al.: Coronary atherosclerotic lesions in human immunodeficiency virus-infected patients: a histopathologic study. Cardiovasc Pathol 2008, 17:117–1123.

Mehta NJ, Khan IA: HIV-associated coronary artery disease. Angiology 2003, 54:269–275.

Stein JH, Hadigan CM, Brown TT, et al., for Working Group 6: Prevention strategies for cardiovascular disease in HIV-infected patients. Circulation 2008, 118:e54–e60.

Savès M, Chêne G, Ducimetière P, et al., for the French WHO MONICA Project and the APROCO (ANRS EP11) Study Group: Risk factors for coronary heart disease in patients treated for human immunodeficiency virus infection compared with the general population. Clin Infect Dis 2003, 37:292–298.

Gritz ER, Vidrine DJ, Lazev AB, et al.: Smoking behavior in a low-income multiethnic HIV/AIDS population. Nicotine Tob Res 2004, 6:71–77.

Kaplan RC, Kingsley LA, Sharrett AR, et al.: Ten-year predicted coronary heart disease risk in HIV-infected men and women. Clin Infect Dis 2007, 45:1074–1081.

Tien PC, Schneider MF, Cole SR, et al.: Antiretroviral therapy exposure and incidence of diabetes mellitus in the Women’s Interagency HIV Study. AIDS 2007, 21:1739–1745.

Hadigan C: Diabetes, insulin resistance, and HIV. Curr Infect Dis Rep 2006, 8:69–75.

Visnegarwala F, Chen L, Raghavan S, Tedaldi E: Prevalence of diabetes mellitus and dyslipidemia among antiretroviral naive patients co-infected with hepatitis C virus (HCV) and HIV-1 compared to patients without co-infection. J Infect 2005, 50:331–337.

Hansson GK: Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med 2005, 352:1685–1695.

Dubé MP, Lipshultz SE, Fichtenbaum CJ, et al.: Working Group 3: Effects of HIV infection and antiretroviral therapy on the heart and vasculature. Circulation 2008, 118:e36–e40.

Solages A, Vita JA, Thornton DJ, et al.: Endothelial function in HIV-infected persons. Clin Infect Dis 2006, 42:1325–1332.

Seigneur M, Constans J, Blann A, et al.: Soluble adhesion molecules and endothelial cell damage in HIV infected patients. Thromb Haemost 1997, 77:646–649.

Melendez MM, McNurlan MA, Mynarcik DC, et al.: Endothelial adhesion molecules are associated with inflammation in subjects with HIV disease. Clin Infect Dis 2008, 46:775–780.

Ehrenreich H, Rieckmann P, Sinowatz F, et al.: Potent stimulation of monocytic endothelin-1 production by HIV-1 glycoprotein 120. J Immunol 1993, 150:4601–4609.

Baker JV, Peng G, Rapkin J, et al.: CD4+ count and risk of non-AIDS diseases following initial treatment for HIV infection. AIDS 2008, 22:841–848.

Kaplan RC, Kingsley LA, Gange SJ, et al.: Low CD4+ T-cell count as a major atherosclerosis risk factor in HIV-infected women and men. AIDS 2008, 22:1615–1624.

Blum A, Hadas V, Burke M, et al.: Viral load of the human immunodeficiency virus could be an independent risk factor for endothelial dysfunction. Clin Cardiol 2005, 28:149–153.

Hsue PY, Lo JC, Franklin A, et al.: Progression of atherosclerosis as assessed by carotid intima-media thickness in patients with HIV infection. Circulation 2004, 109:1603–1608.

Carr A, Samaras K, Burton S, et al.: A syndrome of peripheral lipodystrophy, hyperlipidemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS 1998, 12:F51–F58.

Carr A, Samaras K, Thorisdottir A, et al.: Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study. Lancet 1999, 353:2093–2099.

Mulligan K, Grunfeld C, Tai VW, et al.: Hyperlipidemia and insulin resistance are induced by protease inhibitors independent of changes in body composition in patients with HIV infection. J Acquir Immune Defic Syndr 2000, 23:35–43.

Passalaris JD, Sepkowitz KA, Glesby MJ: Coronary artery disease and human immunodeficiency virus infection. Clin Infect Dis 2000, 31:787–797.

Friis-Møller N, Reiss P, Sabin CA, et al., for the DAD study group: Class of antiretroviral drugs and the risk of myocardial infarction. N Engl J Med 2007, 356:1723–1735.

D:A:D Study Group: Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaboration. Lancet 2008, 371:1417–1425.

Triant VA, Lee H, Hadigan C, Grinspoon SK: Increased acute myocardial infarction rates and cardiovascular risk factors among patients with human immunodeficiency virus disease. J Clin Endocrinol Metab 2007, 92: 2506–2512.

Stein JH: Cardiovascular risks of antiretroviral therapy. N Engl J Med 2007, 356:1773–1775.

D:A:D Study Group: Lipid profiles in HIV-infected patients receiving combination antiretroviral therapy: are different antiretroviral drugs associated with different lipid profiles? J Infect Dis 2004, 189:1056–1074.

Bastard JP, Caron M, Vidal H, et al.: Association between altered expression of adipogenic factor SREBP1 in lipoatrophic adipose tissue from HIV-1-infected patients and abnormal adipocyte differentiation and insulin resistance. Lancet 2002, 359:1026–1031.

Caron M, Auclair M, Vigouroux C, et al.: The HIV protease inhibitor indinavir impairs sterol regulatory element-binding protein-1 intranuclear localization, inhibits preadipocyte differentiation, and induces insulin resistance. Diabetes 2001, 50:1378–1388.

Shankar SS, Dubé MP, Gorski JC, et al.: Indinavir impairs endothelial function in healthy HIV-negative men. Am Heart J 2005, 150:933.e1–933.e37.

Fu W, Chai H, Yao Q, et al.: Effects of HIV protease inhibitor ritonavir on vasomotor function and endothelial nitric oxide synthase expression. J Acquir Immune Defic Syndr 2005, 39:152–158.

Baliga RS, Liu C, Hoyt DG, et al.: Vascular endothelial toxicity induced by HIV protease inhibitor: evidence of oxidant-related dysfunction and apoptosis. Cardiovasc Toxicol 2004, 4:199–206.

•• Wang X, Chai H, Yao Q, Chen C: Molecular mechanisms of HIV protease inhibitor-induced endothelial dysfunction. J Acquir Immune Defic Syndr 2007, 44:493–499. This article outlines the role of ART in endothelial dysfunction.

Dressman J, Kincer J, Matveev SV, et al.: HIV protease inhibitors promote atherosclerotic lesion formation independent of dyslipidemia by increasing CD36-dependent cholesteryl ester accumulation in macrophages. J Clin Invest 2003, 111:389–397.

Sutliff RL, Dikalov S, Weiss D, et al.: Nucleoside reverse transcriptase inhibitors impair endothelium-dependent relaxation by increasing superoxide. Am J Physiol Heart Circ Physiol 2002, 283:H2363–H2370.

Sadr WM, Lundgren JD, Neaton JD, et al., for Strategies for Management of Antiretroviral Therapy (SMART) Study Group: El−, CD4+ count-guided interruption of antiretroviral treatment. N Engl J Med 2006, 355:2283–2296.

Dubé MP, Stein JH, Aberg JA, et al., for Adult AIDS Clinical Trials Group Cardiovascular Subcommittee; HIV Medical Association of the Infectious Disease Society of America: Guidelines for the evaluation and management of dyslipidemia in human immunodeficiency virus (HIV)-infected adults receiving antiretroviral therapy: recommendations of the HIV Medical Association of the Infectious Disease Society of America and the Adult AIDS Clinical Trials Group. Clin Infect Dis 2003, 37:613–627.